Skip to main content
Log in

Aspergillus Lung Disease in Patients with Sarcoidosis: A Case Series and Review of the Literature

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Chronic cavitary pulmonary aspergillosis (CCPA) has been associated with advanced lung diseases. Pulmonary sarcoidosis, a granulomatous inflammatory disorder, is associated with CCPA. We identified CCPA in 2% of cases in a large cohort of sarcoidosis patients. We found a lack of response to medical treatment and poor outcome in this subgroup.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

ATS:

American Thoracic Society

ERS:

European Respiratory Society

BMI:

Body mass index

%DLCO :

Percent predicted diffusion capacity of CO in ml/mmHg/min

FEV1 :

Forced expiratory volume in 1 second

FVC:

Forced vital capacity

COPD:

Chronic obstructive pulmonary disease

CCPA:

Chronic cavitary pulmonary aspergillosis

EORTC/MSG:

European Organization for Research and Treatment of Cancer/Mycosis Study Group

TLC:

Total lung capacity

References

  1. Walsh TJ, Anaissie EJ, Denning DW et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360

    Article  PubMed  CAS  Google Scholar 

  2. Denning DW, Riniotis K, Dobrashian R et al (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 37(Suppl 3):S265–S280

    Article  PubMed  Google Scholar 

  3. Wollschlager C, Khan F (1984) Aspergillomas complicating sarcoidosis. A prospective study in 100 patients. Chest 86(4):585–588

    Article  PubMed  CAS  Google Scholar 

  4. [No authors listed] (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160(2):736–755

    Google Scholar 

  5. Marzouk K, Saleh S, Kannass M et al (2004) Interferon-induced granulomatous lung disease. Curr Opin Pulm Med 10(5):435–440

    Article  PubMed  Google Scholar 

  6. Girard N, Cottin V, Hot A et al (2004) Opportunistic infections and sarcoidosis. Rev Mal Respir 21(6 Pt 1):1083–1090

    PubMed  CAS  Google Scholar 

  7. Baughman RP, Lower EE (2005) Fungal infections as a complication of therapy for sarcoidosis. QJM 98(6):451–456

    Article  PubMed  CAS  Google Scholar 

  8. Lachkar S, Dominique S, Thiberville L et al (2007) Aspergillosis and sarcoidosis. Rev Mal Respir 24(8):943–953

    PubMed  CAS  Google Scholar 

  9. De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821

    Article  PubMed  Google Scholar 

  10. Samarakoon P, Soubani AO (2008) Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature. Chron Respir Dis 5(1):19–27

    Article  PubMed  CAS  Google Scholar 

  11. Muller NL, Kullnig P, Miller RR (1989) The CT findings of pulmonary sarcoidosis: analysis of 25 patients. AJR Am J Roentgenol 152(6):1179–1182

    PubMed  CAS  Google Scholar 

  12. Glimp RA, Bayer AS (1983) Pulmonary aspergilloma. Diagnostic and therapeutic considerations. Arch Intern Med 143(2):303–308

    Article  PubMed  CAS  Google Scholar 

  13. Hance AJ, Basset F, Saumon G et al (1986) Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 465:643–656

    Article  PubMed  CAS  Google Scholar 

  14. Valeyre D, Soler P, Clerici C et al (1988) Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax 43(7):516–524

    Article  PubMed  CAS  Google Scholar 

  15. Hanley ME, King TE Jr, Schwarz MI et al (1991) The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 144(5):1102–1106

    PubMed  CAS  Google Scholar 

  16. Peros-Golubicic T, Ljubic S (1995) Cigarette smoking and sarcoidosis. Acta Med Croatica 49(4–5):187–193

    PubMed  CAS  Google Scholar 

  17. Pfeifer AK, Lange P (2006) Pulmonary consequences of marijuana smoking. Ugeskr Laeger 168(18):1743–1746

    PubMed  Google Scholar 

  18. Kagen SL, Kurup VP, Sohnle PG et al (1983) Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 71(4):389–393

    Article  PubMed  CAS  Google Scholar 

  19. Kagen SL (1981) Aspergillus: an inhalable contaminant of marijuana. N Engl J Med 304(8):483–484

    PubMed  CAS  Google Scholar 

  20. Thornton CR (2010) Detection of invasive aspergillosis. Adv Appl Microbiol 70:187–216

    Article  PubMed  CAS  Google Scholar 

  21. Centeno-Lima S, de Lacerda JM, do Carmo JA et al (2002) Follow-up of anti-Aspergillus IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis. J Clin Lab Anal 16(3):156–162

    Article  PubMed  CAS  Google Scholar 

  22. Sole A, Salavert M (2009) Fungal infections after lung transplantation. Curr Opin Pulm Med 15(3):243–253

    Article  PubMed  Google Scholar 

  23. Bergeron A, Belle A, Sulahian A et al (2010) Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 137(2):410–415

    Article  PubMed  Google Scholar 

  24. Jennings TS, Hardin TC (1993) Treatment of aspergillosis with itraconazole. Ann Pharmacother 27(10):1206–1211

    PubMed  CAS  Google Scholar 

  25. Campbell JH, Winter JH, Richardson MD et al (1991) Treatment of pulmonary aspergilloma with itraconazole. Thorax 46(11):839–841

    Article  PubMed  CAS  Google Scholar 

  26. De Beule K, De Doncker P, Cauwenbergh G et al (1988) The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982–1987). Mycoses 31(9):476–485

    Article  PubMed  Google Scholar 

  27. Dupont B (1990) Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 23(3 Pt 2):607–614

    Article  PubMed  CAS  Google Scholar 

  28. Soltanzadeh H, Wychulis AR, Sadr F et al (1977) Surgical treatment of pulmonary aspergilloma. Ann Surg 186(1):13–16

    Article  PubMed  CAS  Google Scholar 

  29. Guerra M, Santos N, Miranda J et al (2008) Surgical management of pulmonary aspergilloma. Rev Port Cir Cardiotorac Vasc 15(3):135–138

    PubMed  Google Scholar 

  30. Chen JC, Chang YL, Luh SP et al (1997) Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 52(9):810–813

    Article  PubMed  CAS  Google Scholar 

  31. Brik A, Salem AM, Kamal AR et al (2008) Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg 34(4):882–885

    Article  PubMed  Google Scholar 

  32. Caidi M, Kabiri H, Al Aziz S et al (2006) Surgical treatment of pulmonary aspergilloma. 278 cases. Presse Med 35(12 Pt 1):1819–1824

    Article  PubMed  Google Scholar 

  33. Camuset J, Nunes H, Dombret MC et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131(5):1435–1441

    Article  PubMed  Google Scholar 

  34. Felton TW, Baxter C, Moore CB et al (2010) Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 51(12):1383–1391

    Article  PubMed  CAS  Google Scholar 

  35. Lee KS, Kim HT, Kim YH et al (1993) Treatment of hemoptysis in patients with cavitary aspergilloma of the lung: value of percutaneous instillation of amphotericin B. AJR Am J Roentgenol 161(4):727–731

    PubMed  CAS  Google Scholar 

  36. Rumbak M, Kohler G, Eastrige C et al (1996) Topical treatment of life threatening haemoptysis from aspergillomas. Thorax 51(3):253–255

    Article  PubMed  CAS  Google Scholar 

  37. Kaplan J, Johns CJ (1979) Mycetomas in pulmonary sarcoidosis: non-surgical management. Johns Hopkins Med J 145(4):157–161

    PubMed  CAS  Google Scholar 

  38. Idali F, Wikén M, Wahlström J et al (2006) Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J 27(3):451–459

    Article  PubMed  CAS  Google Scholar 

  39. Chaudhary N, Staab JF, Marr KA (2010) Healthy human T-cell responses to Aspergillus fumigatus antigens. PLoS One 5(2):e9036

    Article  PubMed  Google Scholar 

  40. Judson MA (2009) Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance. Chest 135(5):1358–1359

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by the Department of Medicine, Wayne State University School of Medicine (LS).

Disclosures

T. A. Pena, A. O. Soubani, and L. Samavati have no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lobelia Samavati.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pena, T.A., Soubani, A.O. & Samavati, L. Aspergillus Lung Disease in Patients with Sarcoidosis: A Case Series and Review of the Literature. Lung 189, 167–172 (2011). https://doi.org/10.1007/s00408-011-9280-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-011-9280-9

Keywords

Navigation